Ana M Basso

Summary

Affiliation: Abbott Laboratories
Country: USA

Publications

  1. ncbi request reprint Antidepressant-like effect of D(2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test
    Ana M Basso
    Abbott Laboratories, Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Park, IL 60064, USA
    Neuropsychopharmacology 30:1257-68. 2005
  2. ncbi request reprint Lack of efficacy of melanin-concentrating hormone-1 receptor antagonists in models of depression and anxiety
    Ana M Basso
    Neuroscience, Abbott Laboratories, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Eur J Pharmacol 540:115-20. 2006
  3. doi request reprint Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: relevance for neuropsychiatric disorders
    Ana M Basso
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Behav Brain Res 198:83-90. 2009
  4. doi request reprint Vogel conflict test: sex differences and pharmacological validation of the model
    Ana M Basso
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Behav Brain Res 218:174-83. 2011
  5. doi request reprint Behavioral characterization of a mutant mouse strain lacking D-amino acid oxidase activity
    Min Zhang
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Behav Brain Res 217:81-7. 2011
  6. ncbi request reprint The drug-induced helplessness test: an animal assay for assessing behavioral despair in response to neuroleptic treatment
    Michael E Ballard
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Psychopharmacology (Berl) 190:1-11. 2007
  7. doi request reprint Preclinical evaluation of non-imidazole histamine H3 receptor antagonists in comparison to atypical antipsychotics for the treatment of cognitive deficits associated with schizophrenia
    Jordan W Brown
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Int J Neuropsychopharmacol 16:889-904. 2013
  8. doi request reprint Xanomeline modulation of the blood oxygenation level-dependent signal in awake rats: development of pharmacological magnetic resonance imaging as a translatable pharmacodynamic biomarker for central activity and dose selection
    Scott Baker
    Translational Sciences, Advanced Technology, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL, USA
    J Pharmacol Exp Ther 341:263-73. 2012
  9. doi request reprint Structural abnormalities revealed by magnetic resonance imaging in rats prenatally exposed to methylazoxymethanol acetate parallel cerebral pathology in schizophrenia
    Chih Liang Chin
    Advanced Technology, Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA
    Synapse 65:393-403. 2011

Detail Information

Publications9

  1. ncbi request reprint Antidepressant-like effect of D(2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test
    Ana M Basso
    Abbott Laboratories, Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Park, IL 60064, USA
    Neuropsychopharmacology 30:1257-68. 2005
    ..The pharmacological selectivity of the compounds tested suggests that the antidepressant-like effects of quinpirole are most likely mediated mainly by D(2) and to a lesser extent by D(3) but not D(4) receptors...
  2. ncbi request reprint Lack of efficacy of melanin-concentrating hormone-1 receptor antagonists in models of depression and anxiety
    Ana M Basso
    Neuroscience, Abbott Laboratories, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Eur J Pharmacol 540:115-20. 2006
    ..The lack of efficacy with four structurally different MCH-1 receptor antagonists does not support a role for therapeutic treatment of depression/anxiety via this mechanism of action...
  3. doi request reprint Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: relevance for neuropsychiatric disorders
    Ana M Basso
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Behav Brain Res 198:83-90. 2009
    ..These data support the relevance of pro-inflammatory cytokines in depressive-like states, and suggest that P2X(7) receptor antagonists could be of potential interest for the treatment of affective disorders...
  4. doi request reprint Vogel conflict test: sex differences and pharmacological validation of the model
    Ana M Basso
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Behav Brain Res 218:174-83. 2011
    ..This investigation highlights the importance of using female subjects in the preclinical research of anxiety and the screening of anxiolytic compounds in the drug development process...
  5. doi request reprint Behavioral characterization of a mutant mouse strain lacking D-amino acid oxidase activity
    Min Zhang
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Behav Brain Res 217:81-7. 2011
    ..Our data suggest that DAO-/- mice might have altered functioning of NMDARs. However, these results provide only modest support for manipulations of DAO activity as a potential therapeutic approach to treat schizophrenia...
  6. ncbi request reprint The drug-induced helplessness test: an animal assay for assessing behavioral despair in response to neuroleptic treatment
    Michael E Ballard
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Psychopharmacology (Berl) 190:1-11. 2007
    ..Neuroleptic dysphoria encompasses a range of unpleasant subjective responses and, as a result, is difficult to study in preclinical animal models...
  7. doi request reprint Preclinical evaluation of non-imidazole histamine H3 receptor antagonists in comparison to atypical antipsychotics for the treatment of cognitive deficits associated with schizophrenia
    Jordan W Brown
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Int J Neuropsychopharmacol 16:889-904. 2013
    ..Chronic, but not acute, treatment with ABT-239 significantly improved spontaneous alternation impairments in MAM rats tested in cross-maze. In summary, these results suggest H(3)R antagonists may have the potential to ameliorate CDS...
  8. doi request reprint Xanomeline modulation of the blood oxygenation level-dependent signal in awake rats: development of pharmacological magnetic resonance imaging as a translatable pharmacodynamic biomarker for central activity and dose selection
    Scott Baker
    Translational Sciences, Advanced Technology, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL, USA
    J Pharmacol Exp Ther 341:263-73. 2012
    ....
  9. doi request reprint Structural abnormalities revealed by magnetic resonance imaging in rats prenatally exposed to methylazoxymethanol acetate parallel cerebral pathology in schizophrenia
    Chih Liang Chin
    Advanced Technology, Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA
    Synapse 65:393-403. 2011
    ..The MAM model incorporating noninvasive imaging techniques may therefore serve as an improved translational research tool for assessing new treatments for schizophrenia...